# **Supporting Information**

### **Table of Contents**

1.	General information
2.	The method for the synthesis of quinone substrates
3.	Optimization of the reaction conditions
4.	General procedure for the catalytic enantioselective quinone-fulvene [2 + 2]
	cycloadditionsS12
5.	The analytical and spectral characterization data of the products (3aa-3ua,
	<b>3ab-3ao</b> )
6.	Other o-substituted quinones and substituted fulvenes which are not suitable for
	this [2+2] cycloaddition reaction
7.	General Procedure for the isomerization of the product <b>3</b>
8.	Preparative scale synthesis of the product <b>3aa</b> and <b>ent-3an</b>
9.	Synthetic transformations of the product <b>3aa</b> and <b>ent-3an</b>
10.	X-ray crystalstructure of the product <b>3aa</b> and <b>ent-4an</b>
11.	Operando IRexperiments
12.	NMR spectra

#### **1.** General information

<sup>1</sup>H NMR spectra were recorded on commercial instruments (400 MHz). Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl<sub>3</sub>,  $\delta = 7.26$ ). Spectra were reported as follows: chemical shift ( $\delta$  ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), integration and assignment. <sup>13</sup>C NMR spectra were collected on commercial instruments (100 MHz) with complete proton decoupling. Chemical shifts are reported in ppm from the tetramethylsilane with the solvent resonance as internal standard (CDCl<sub>3</sub>,  $\delta = 77.0$ ).

Enantiomeric ratio (*e.r.*) were determined by HPLC analysis using the corresponding commercial chiralpak column as stated in the experimental procedures at 25 °C. The chiralpak column Lux 5u Cellulose-2 and the chiralpakLux 5u cellulose-3 were purchased from phenomenex company.

Optical rotations were reported as follows:  $[a]_D^{25}$  (c: g/100 mL, in solvent).

HRMS was recorded on a commercial apparatus (ESI Source).

All catalytic reactions were run in dried glassware or test tube.

THF, toluene and diethyl ether ( $Et_2O$ ) were distilled from sodium and benzophenone as indicator.

CH<sub>3</sub>CN and CH<sub>2</sub>Cl<sub>2</sub> was distilled over CaH<sub>2</sub>.

Cu(OTf)<sub>2</sub> (99%), Ag<sub>2</sub>O were purchased from Alfa.

All racemic products (**3aa-3ua, 3ab-3ao**) were obtained by using  $Cu(OTf)_2$  (10 mol%) and racemic *N*,*N*-dioxide ligand (**L-RaPr**<sub>2</sub> or **L-RaPr**<sub>3</sub>, 10 mol%) as the catalyst according to general procedure for the catalytic enantioselective quinone – fulvene [2 + 2] cycloadditions.

Quinone substrates (1a, 1g) were synthesized by using the literature method (J. Jacobs, S. Claessens, B. M. Mbala, K. Huygen, N. D. Kimbe, *Tetrahedron*, 2009, 65, 1193-1199).

Fulvenes were obtained by using the literature method (K. J. Stone, R. D. Little, *J. Org. Chem*, **1984**, *49*, 1853-1857; I. Erden, F. P. Xu, A. Sadoun, W. Smith, G. Sheff, M. Ossun, *J. Org. Chem*. **1995**, *60*, 813-820).

#### 2. The method for the synthesis of quinone substrates <sup>1</sup>



To a solution of benzoquinone (20 mmol, 1.0 equiv) in dichloromethane (100 mL) was added the corresponding boronic acid (30 mmol, 1.5 equiv), water (100 mL), and silver(I) nitrate (680 mg, 4.0 mmol, 0.2 equiv). Potassium persulfate (16.2 g, 60 mmol, 3.0 equiv) was then added and the solution was stirred vigorously at room temperature and monitored by thin-layer chromatography analysis of the organic layer. Upon consumption of quinone (3 - 24 h), the reaction was diluted with dichloromethane (50 mL). The layers were separated, and the aqueous layer was extracted with dichloromethane (3 x30 mL), dried over sodium sulfate, and evaporated in vacuo. The product was used for next step with silica gel quick purification.

To a solution of corresponding substituted benzoquinone in CH<sub>3</sub>CN (30 mL), trimethylsilylbromide (TMSBr, 30 mmol, 4.0 mL) was added. and tetraethylammonium fluoroborate (TBAF, 1.0 M in THF, 1.5 mmol, 1.5 mL) in CH<sub>3</sub>CN (10 mL) was carefully added, at which time the quinone color was disappeared. The reaction mixture was stirred for 2 hours at room temperature. After removal of solvent in vacuo, the resulted mixture was mixed with water (10 mL) and ethyl acetate (30 mL). The aqueous layer was separated and extracted with ethyl acetate twice (2 x 15 mL). The organic layers were combined and dried over sodiumsulfate, filtrated and removal of the solvent in vacuo. Purification was performed by silica gel chromatography to yield the pure product.

To a solution of the corresponding bromo-substituted benzene-1,4-diol (10 mmol) in DMF (15 mL), Pd(dppf)Cl<sub>2</sub> (0.75 g, 1.0 mmol), MeOH (6 mL), Bu<sub>3</sub>N (2.74 mL, 14.8 mmol) was added in sequence. The vessel was purged and pressurized with CO (4.0 MPa) and stirred at 110 °C for 24 h. The reaction was cooled to room temperature, diluted with  $CH_2Cl_2$  (50 mL), washed with 1N HCl (2 x 35 mL), brine/water (1:1, 35 mL), and brine (35 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford a dark purple oil. The residue was purified by flash chromatography (5-10% EtOAc/hexanes) to afford the titled compound as a white solid.

a) Y. Fujiwara, V. Domingo, I. B. Seiple, R.Gianatassio, M. D. Bel, and P. S. Baran, J. Am. Chem. Soc. 2011, 133, 3292-3295; b) M.Nakazaki, K.Naemura, J. Org. Chem. 1981, 46, 106-111; c) L. L. Miller, R. F. Stewart, J. Org. Chem. 1978, 43, 3078-3079; d) D. A. Evans, J. M. Wu, J. Am. Chem. Soc. 2003, 125, 10162-10163.



Methyl-2,5-dihydroxy-[1,1'-biphenyl]-4-carboxylate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.31 (s, 1H), 7.55 – 7.39 (m, 6H), 6.90 (s, 1H), 4.82 (s, 1H), 3.95 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.1, 155.4, 144.8, 136.5, 135.9, 129.3, 128.7, 128.7, 118.6, 115.6, 111.9, 52.4.



Methyl-2,5-dihydroxy-2'-methyl-[1,1'-biphenyl]-4-carboxylate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.34 (s, 1H), 7.43 (s, 1H), 7.34 – 7.31 (m, 2H), 7.29 – 7.26 (m, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 6.78 (s, 1H), 4.48 (s, 1H), 3.96 (s, 3H), 2.18 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 155.2, 145.1, 136.8, 136.5,

134.7, 130.8, 129.7, 129.1, 126.5, 118.6, 114.9, 112.1, 52.4, 19.6.



Methyl-2,5-dihydroxy-3'-methyl-[1,1'-biphenyl]-4-carboxylate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.30 (s, 1H), 7.41 (s, 1H), 7.37 (d, *J* = 7.6 Hz, 1H), 7.29 – 7.22 (m, 3H), 6.89 (s, 1H), 4.93 (s, 1H), 3.95 (s, 3H), 2.41 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.3, 144.9, 139.2, 136.6, 135.8, 129.5, 129.4, 129.3, 125.7, 118.5, 115.4, 111.8, 52.4, 21.5.



Methyl-4'-(tert-butyl)-2,5-dihydroxy-[1,1'-biphenyl]-4-carboxyla te

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.31 (s, 1H), 7.52 (d, *J* = 7.6 Hz, 2H), 7.45–7.40 (m, 3H), 6.91 (s, 1H), 4.89 (s, 1H), 3.96 (s, 3H),

1.37 (s, 9H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.4, 151.8, 144.9, 136.5, 132.9, 128.4, 126.3, 118.5, 115.4, 52.4, 34.7, 31.3.



Methyl-4'-fluoro-2,5-dihydroxy-[1,1'-biphenyl]-4-carboxylate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.31 (s, 1H), 7.53 – 7.43 (m, 2H), 7.41 (s, 1H), 7.22 – 7.14 (m, 2H), 6.89 (s, 1H), 4.70 (s, 1H), 3.96 (d, *J* = 1.2 Hz, 3H);

F<sup>-13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.9, 155.5, 144.8, 135.6, 132.0, 130.8, 130.7, 118.7, 116.3, 116.1, 115.7, 111.9, 52.4.



Methyl-4'-ethoxy-2,5-dihydroxy-[1,1'-biphenyl]-4-carboxylate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.30 (s, 1H), 7.45 – 7.35 (m, 3H), 7.00 (d, *J* = 7.6 Hz, 2H), 6.88 (s, 1H), 4.84 (s, 1H), 4.08 (q, *J* = 6.8 Hz, 2H), 3.95 (s, 3H), 1.45 (t, *J* = 6.8 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 159.3, 155.5, 144.9, 136.4,

130.0, 127.9, 118.4, 115.4, 115.3, 111.43, 63.6, 52.4, 14.8.

Methyl-2,5-dihydroxy-4-methylbenzoate



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.29 (s, 1H), 7.19 (s, 1H), 6.77 (s, 1H), 4.69 (s, 1H), 3.91 (s, 3H), 2.26 (s, 3H);
<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 155.7, 146.3, 134.6, 119.4, 113.9, 109.8, 52.22, 16.6.



Methyl-4-ethyl-2,5-dihydroxybenzoate

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.29 (s, 1H), 7.18 (s, 1H), 6.79 (s, 1H), 4.62 (s, 1H), 3.91 (s, 3H), 2.63 (q, *J* = 7.6 Hz, 2H), 1.23 (td, *J* = 7.6, 1.6 Hz, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 155.9, 145.9, 140.5, 117.7, 3.4, 13.3.

114.2, 109.6, 52.2, 23.4, 13.3.



Methyl-2,5-dihydroxy-4-isopropylbenzoate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.27 (s, 1H), 7.18 (s, 1H), 6.84 (s, 1H), 4.49 (s, 1H), 3.92 (s, 3H), 3.42 – 3.05 (m, 1H), 1.24 (d, *J* = 6.8 Hz, 6H);

OH <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 156.3, 145.3, 145.0, 115.3, 114.3, 109.5, 52.2, 27.6, 22.2.



Methyl-2,5-dihydroxy-4-isobutylbenzoate

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.27 (s, 1H), 7.19 (s, 1H), 6.73 (s, 1H), 4.54 (s, 1H), 3.91 (s, 3H), 2.47 (d, *J* = 7.2 Hz, 2H), 2.0 –1.90 (m, 1H), 1.05 – 0.81 (m, 6H);

OH <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 155.6, 146.2, 138.2, 119.5, 114.4, 109.9, 52.2, 39.66, 28.6, 22.5.



Methyl-4-(tert-butyl)-2,5-dihydroxybenzoate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.17 (s, 1H), 7.09 (s, 1H), 6.92 (s, 1H), 4.62 (s, 1H), 3.91 (s, 3H), 1.39 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  169.9, 155.6, 146.7, 146.5, 116.2, 115.2, 109.5, 52.2, 35.3, 29.1.



Methyl-4-cyclopentyl-2,5-dihydroxybenzoate

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.29 (s, 1H), 7.18 (s, 1H), 6.84 (s, 1H), 4.73 (s, 1H), 3.91 (s, 3H), 3.45 – 3.06 (m, 1H), 2.10 – 2.00 (m, 2H), 1.84 – 1.74 (m, 2H), 1.75 – 1.65 (m, 2H), 1.64 – 1.52 (m, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.9, 145.9, 142.9, 115.6, 114.2, 109.4, 52.2, 39.5, 32.6, 25.3.



115.7, 114.3, 109.4, 52.2, 37.8, 32.6, 26.8, 26.1.



Methyl-2,5-dihydroxy-4-phenethylbenzoate <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.27 (s, 1H), 7.31 – 7.27 (t, J = 7.5 Hz, 2H), 7.23 – 7.19 (m, 2H), 7.18 (s, 2H), 6.76 (s, 1H), 4.38 (s, 1H), 3.91 (d, J = 0.6 Hz, 3H), 2.91 (s, 4H);

OH <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.9, 145.9, 141.3, 138.3, 128.5, 128.4, 126.2, 118.7, 114.7, 110.1, 52.24, 35.7, 32.7.



To a 25 mL round-bottom flask was added 2,5-dihydroxy-bznzoic acid methyl ester (1.0 mmol), MgSO<sub>4</sub> (dried at 300 °C for 2.0 h before use, 360 mg, 3 mmol), and Et<sub>2</sub>O (dry, 20 mL). The solution was added Ag<sub>2</sub>O (700 mg, 3.0 mmol), and then stirred for 2.0 h at room temperature. The reaction mixture was then filtered, washed with 10 mL of Et<sub>2</sub>O (dry), and concentrated under reduced pressure at room temperature to afford the quinone product. The product was immediately used without further purification. (The product is sensitive to acid, H<sub>2</sub>O and light, and stable at -20 °C for at least one week without any noticeable polymerization as judged by <sup>1</sup>H NMR spectroscopy )

#### 3. Optimization of the reaction conditions

Table 1: Preliminary results of the reaction between quinone (1) and fulvene (2a)

0 + 0 1 2a	M/L-PiPr <sub>2</sub> (1: CH <sub>2</sub> Cl <sub>2</sub> , 30	1, 10 mol%) ) °C, 36 h	H H H H H H H S	+ HO H HO H H H H H H H H
Entry <sup>a</sup>	Metalsalt		3	
		Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	Eed
1	Sc(OTf) <sub>3</sub>	83	>20:1	0
2	Y(OTf) <sub>3</sub>	78	>20:1	0
3	Yb(OTf) <sub>3</sub>	81	>20:1	0
4	La(OTf) <sub>3</sub>	64	>20:1	0
5	Er(OTf) <sub>3</sub>	67	>20:1	0

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-PiPr<sub>2</sub>–M** (1:1, 10 mol%), **1**(0.1 mmol) and **2a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at 30 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio was determined by HPLC analysis on chiral stationary phases.

$ \begin{array}{c} 0 \\ 0 \\ 0 \\ 1 \end{array} $	Sc(OTf) <sub>3</sub> /L (1:1, CH <sub>2</sub> Cl <sub>2</sub> , -10 °C	10 mol%) , 36 h		0	Ph H O H 4
Entry	L		3		
		Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	Eed	
1	L-PiPr <sub>2</sub>	64	>20:1	11%	_
2	L-PrPr <sub>2</sub>	73	>20:1	8%	
3	L-RaPr <sub>2</sub>	68	>20:1	5%	

Table 2: Screening the ligands of [2+2] reaction

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with L–Sc(OTf)<sub>3</sub> (1:1, 10 mol%), 1(0.1 mmol) and 2a(0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at -10 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio was determined by HPLC analysis on chiral stationary phases.

	$H_3 \xrightarrow{\text{M/L-RaPr}_2(r)} \frac{\text{M/L-RaPr}_2(r)}{\text{CH}_2\text{Cl}_2, -1}$	1:1, 10 mol%) 0 °C, 36 h	CO <sub>2</sub> CH <sub>3</sub> H H H 3aa	H <sub>3</sub> CO <sub>2</sub> C HO HO H H H H H H
Entry <sup>a</sup>	Metal salt		3aa	
		Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>
1	$Co(ClO_4)_2 \cdot 6H_2O$	trace	-	-
2	Zn(OTf) <sub>2</sub>	25	64:36	50:50
3	Mg(OTf) <sub>2</sub>	53	94:6	87:13
4	Ni(OTf) <sub>2</sub>	62	73:27	72:28
5	Cu(OTf) <sub>2</sub>	31	94:6	90:10

Table 3: Screening the metal salts of the reaction of quinone (1a)

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-RaPr<sub>2</sub>–M** (1:1, 10 mol%), **1a** (0.1 mmol) and **2a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at -10 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

Table 4: Screening the ligands of the [2+2] reaction of quinone (1a)

O O O 1a	CO <sub>2</sub> CH <sub>3</sub> / + 2	Cu(OTf) <sub>2</sub> /L (1) CH <sub>2</sub> Cl <sub>2</sub> , -1	:1, 10 mol%) 0 °C, 36 h	GO <sub>2</sub> CH <sub>3</sub> H H H H H H H H H H H H H H H H H	H <sub>3</sub> CO <sub>2</sub> C HO HO H H H H H H
	Entry <sup>a</sup>	L		3aa	
			Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>
	1	Box	Trace	-	-
	2	L-PiPr <sub>2</sub>	41	72:28	50:50
	3	L-PrPr <sub>2</sub>	25	95:5	94:6
	4	L-RaPr <sub>2</sub> Br	60	90:10	88:12
	5	L-RaPr <sub>2</sub> <sup>t</sup> Bu	68	90:10	90:10
	6	L-RaPr <sub>3</sub>	56	94:6	94:6

<sup>&</sup>lt;sup>*a*</sup> Unless otherwise noted, the reactions were performed with L-Cu(OTf)<sub>2</sub> (1:1, 10 mol%), **1a** (0.1 mmol) and **2a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at -10 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>Thed.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

O O O 1a	O <sub>2</sub> CH <sub>3</sub> + 2a	Cu(OTf) <sub>2</sub> /L-Ral	Pr <sub>3</sub> (1:1, 10 mol%) Temp, 36 h	CO <sub>2</sub> CH <sub>3</sub> - H H H 3aa	+ HO H + HO H + 4aa
	Entry <sup>a</sup>	Temp.		3aa	
			Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>
	1	-10°C	56	94:6	92:8
	2	-20°C	62	94:6	94:6
	3	-30°C	62	94:6	95:5
	4	-40°C	63	94:6	97:3
	5	-60°C	46	94:6	97:3

Table 5: Screening the temperature of the [2+2] reaction of quinone (1a)

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-RaPr<sub>3</sub>–**Cu(OTf)<sub>2</sub> (1:1, 10 mol%), **1a** (0.1 mmol) and **2a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at the reaction temperature for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

Table 6: Screening the solvents of the [2+2] reaction of quinone (1a)

0 0 1a	CO <sub>2</sub> CH <sub>3</sub> / + 2	Cu(OTf) <sub>2</sub> /L-F	<b>RaPr<sub>3</sub> (1:1, 10 mol%)</b> ★ ht, -40 °C, 36 h	O <u>CO</u> <sub>2</sub> CH, H H H S 3aa	H <sub>3</sub> CO <sub>2</sub> C + HO	H H 4aa
	Entry <sup>a</sup>	Solvent		3aa		
		_	Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>	
-	1	CHCl <sub>3</sub>	Trace	-	-	-
	2	CH <sub>2</sub> Cl <sub>2</sub>	63	94:6	97:3	
	3	THF	Trace	-	-	
	4	Toluene	Trace	-	-	
	5	EtOAc	Trace	-	-	
	6	CH <sub>3</sub> CN	73	94:6	98.5:1.5	

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-RaPr<sub>3</sub>**–Cu(OTf)<sub>2</sub> (1:1, 10 mol%), **1a** (0.1 mmol) and **2a** (0.15 mmol) in solvent (1.0 mL) at -40 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>c</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

O O O 1a	CO <sub>2</sub> CH <sub>3</sub> +	Cu(OTf) <sub>2</sub> /L-1 CH <sub>3</sub> C	RaPr <sub>3</sub> (1:1, 10 mol%) N, -40 °C, 36 h Additive		H <sub>3</sub> H H <sub>3</sub> CO <sub>2</sub> C H HO	H H 4aa
-	Entry <sup>a</sup>	Additive		3aa		
			Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>	
-	1	3ÅMS	78	94:6	98.5:1.5	
	2	4ÅMS	74	94:6	98.5:1.5	
	3	5ÅMS	45	94:6	98.5:1.5	

Table 7: Screening the additives of the [2+2] reaction of quinone (1a)

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-RaPr**<sub>3</sub>–Cu(OTf)<sub>2</sub> (10 mol%), **1a** (0.1 mmol), MS (10 mg) and **2a** (0.15 mmol) in CH<sub>3</sub>CN (1.0 mL) at -40 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

Table 8: Screening the ratio of the metal and the ligand for the [2+2] reaction

O ↓ O ↓ O 1a	CO₂CH₃ ⟨ + ;	Cu(OTf	:)₂ <b>/L-RaPr₃</b> (M/L, 10 mol%) CH₃CN, -40 ºC, 36 h 3 Å MS	O CO <sub>2</sub> CH H H H J J A	H <sub>3</sub> CO <sub>2</sub> C + HO	H H H H H H
-	Entry <sup>a</sup>	M/L		3aa		_
			Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>	
_	1	1:1	78	94:6	98.5:1.5	_
	2	1:1.1	82	94:6	98.5:1.5	
	3	1.5:1	Trace	-	-	

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with **L-RaPr<sub>3</sub>–**Cu(OTf)<sub>2</sub> (10 mol%), **1a** (0.1 mmol), 3Å MS(10 mg) and **2a** (0.15 mmol) in CH<sub>3</sub>CN (1.0 mL) at -40 °C for 36 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

	CO <sub>2</sub> CH <sub>3</sub> + + + + + + + + + + + + + + + + + + +	M/L (10 mol%) CH <sub>2</sub> Cl <sub>2</sub> , -10 °C, 48 h	GO2CH3 H H30 H H0 3aa	CO <sub>2</sub> C H H 4aa	
Entry <sup>a</sup>	L	Metal		4aa	
			Yield(%) <sup>b</sup>	D.r. <sup>c</sup>	E.r. <sup>d</sup>
1	L-RaPr <sub>2</sub>	In(OTf) <sub>3</sub>	trace	-	-
2	L-RaPr <sub>2</sub>	Mg(OTf) <sub>2</sub>	31	N.D	56:44
3	L-RaPr <sub>2</sub>	$Mg(NTf_2)_2$	45	97:3	64.5:35.5
4	L-RaPr <sub>2</sub>	Co(ClO <sub>4</sub> ) <sub>2</sub> .6H <sub>2</sub> O	40	97:3	67:33
5	L-RaPr <sub>2</sub>	Cu(OTf) <sub>2</sub> /NaBAr <sup>F</sup> <sub>4</sub>	23	94:6	70.5:29.5
6	L-RaPr <sub>3</sub>	Co(ClO <sub>4</sub> ) <sub>2</sub> .6H <sub>2</sub> O	49	99:1	56.5:43.5
7	L-PrPr <sub>2</sub>	Co(ClO <sub>4</sub> ) <sub>2</sub> .6H <sub>2</sub> O	7	98:2	63:37
8	L-PrPr <sub>3</sub>	Co(ClO <sub>4</sub> ) <sub>2</sub> .6H <sub>2</sub> O	8	97:3	66.5:33.5
9	L-PiPr <sub>2</sub>	Co(ClO <sub>4</sub> ) <sub>2</sub> .6H <sub>2</sub> O	13	97:3	0
10	L-RaPr <sub>3</sub>	Mg(NTf <sub>2</sub> ) <sub>2</sub>	42	97:3	53:47
11	L-PrPr <sub>2</sub>	Mg(NTf <sub>2</sub> ) <sub>2</sub>	trace	-	-
12	L-PrPr <sub>3</sub>	Mg(NTf <sub>2</sub> ) <sub>2</sub>	trace	-	-
13	L-PiPr <sub>2</sub>	Mg(NTf <sub>2</sub> ) <sub>2</sub>	16	97:3	0

0

Table 9. Optimization the conditions of [3+2] reaction

<sup>*a*</sup> Unless otherwise noted, the reactions were performed with L-M (1:1, 10 mol%), **1a** (0.1 mmol) and **2a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) at -10 °C for 48 h. <sup>*b*</sup>Isolated yield. <sup>*c*</sup>The d.r. was determined by <sup>1</sup>H NMR and HPLC analysis. <sup>*d*</sup>Enantiometric ratio of the major isomer was determined by HPLC analysis on chiral stationary phases.

## **4.** General procedure for the catalytic enantioselective quinone–fulvene [2 + 2]



In a test tube with a magnetic stirring bar N,N-dioxide **L-RaPr**<sub>3</sub> (0.011mmol), Cu(OTf)<sub>2</sub> (0.01 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) were stirred at 35 °C for 1h. After

removing CH<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN (1.0 mL) was added. The mixture was cooled to -40 °C, and the quinone (**1a-1u**) (0.1 mmol), 3Å MS (10 mg), and fulvene (**2a-2o**) (0.15 mmol, 1.5 equiv.) were added in sequence. The mixture was stirred at -40 °C for 36 h. The reaction mixture was detected by TLC. After completion, flash column chromatography was carried out to provide the desired product (**3aa–3ua, 3ab-3ao**). The product was used immediately for HPLC and NMR analysis.

### 5. The analytical and spectral characterization data of the products (3aa-3ua,

3ab-3ao)



methyl-(3aR,3bR,7aR,7bS)-1-((Z)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7b-hex ahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate;

yellow oil; 82% yield, 98.5:1.5 e.r., 94:6 d.r.;  $[a]_D^{25} = -489.8$  (c 0.52, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 17.47$  min, $t_2 = 18.78$  min,  $t_3 = 28.52$  min,  $t_4 = 31.11$  min];

<sup>1</sup>H NMR (400 MHz, CDCl3)  $\delta$  7.35 – 7.29 (m, 4H), 7.26 – 7.20 (m, 1H), 6.92 (s, 2H), 6.56 (s, 1H), 6.53 – 6.49 (m, 1H), 6.30 (dd, J = 5.2, 2.8 Hz, 1H), 3.95 – 3.89 (m, 1H), 3.84 – 3.78 (m, 2H), 3.75 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl3) δ 195.3, 193.1, 167.0, 146.9, 141.8, 140.6, 139.9, 136.4, 133.1, 128.4, 127.9, 127.3, 125.1, 59.9, 54.0, 53.1, 52.3, 41.6;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>20</sub>H<sub>17</sub>O<sub>4</sub>, m/z: 321.1127, observed: 321.1124.



		Retention Time	Area	% Area
--	--	----------------	------	--------

1	17.476	945994	1.42
2	31.113	65751448	98.58



Ethyl-(3aR,3bR,7aR,7bS)-1-((Z)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7b-hexa hydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate Yellow oil; 67% yield, 97.5:2.5 e.r., 97:3 d.r.;  $[a]_D^{25} = -497.1$  (c 0.17, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 14.22$  min, $t_2 = 21.12$  min,  $t_3 = 22.60$  min,  $t_4 = 25.19$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31 (m, 4H), 7.22 (m, 1H), 6.91 (s, 2H), 6.55 (s, 1H), 6.50 (d, J = 5.4 Hz, 1H), 6.31 (dd, J = 5.2, 2.8 Hz, 1H), 4.29 – 4.13 (m, 2H), 3.92 –3.90 (m, 1H), 3.86 – 3.75 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.5, 193.2, 166.5, 147.1, 141.8, 140.6, 139.8, 136.4, 133.3, 128.4, 127.9, 127.3, 125.1, 123.9, 118.5, 114.7, 62.3, 59.9, 53.9, 52.4, 41.5, 14.2. HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>21</sub>H<sub>19</sub>O<sub>4</sub>, m/z: 335.1283, observed: 335.1283.



	Retention Time	Area	% Area
1	14.224	516172	2.44
2	25.190	20625833	97.56



propyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7b-hex ahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate Yellow oil; 60% yield, 97:3 e.r., 97:3 d.r.;  $[a]_D^{25} = -558.2$  (c 0.69, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 13.16 min,t<sub>2</sub> = 14.13 min, t<sub>3</sub> = 19.96 min, t<sub>4</sub> = 21.05 min]; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 – 7.27 (m, 4H), 7.25 – 7.17 (m, 1H), 6.90 (d, *J* = 1.2 Hz, 2H), 6.54 (s, 1H), 6.49 (d, *J* = 5.6 Hz, 1H), 6.34 – 6.26 (m, 1H), 4.12 – 4.06 (m, 2H), 3.92 – 3.80 (m, 1H), 3.81 – 3.76 (m, 2H), 1.69 – 1.60 (m, 2H), 0.90 (t, *J* = 7.6 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  195.5, 193.2, 166.6, 147.1, 141.8, 140.6, 139.7, 136.4, 133.4, 128.4, 127.9, 127.3, 125.0, 67.7, 60.0, 53.8, 52.5, 41.6, 21.9, 10.3;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>22</sub>H<sub>21</sub>O<sub>4</sub>, m/z: 349.1440, observed: 349.1438.



	Retention Time	Area	% Area
1	13.164	763432	2.54
2	21.050	29326333	97.46



butyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7b-hexa hydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate

Yellow oil; 60% yield, 97:3 e.r., 97:3 d.r.;  $[a]_D^{25} = -543.2$  (c 0.83, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 12.53$  min, $t_2 = 13.30$  min,  $t_3 = 18.66$  min,  $t_4 = 19.83$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35 – 7.28 (m, 4H), 7.26 – 7.17 (m, 1H), 6.91 (s, 2H), 6.55 (s, 1H), 6.49 (d, J = 5.6 Hz, 1H), 6.31 (d, J = 2.0 Hz, 1H), 4.13 (t, J = 6.4 Hz, 2H), 3.90 (s, 1H), 3.81 – 3.75 (m, 2H), 1.66 – 1.56 (m, 2H), 1.40 – 1.25 (m, 2H), 0.95 – 0.87 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.5, 193.2, 166.6, 147.1, 141.8, 140.6, 139.7, 136.4, 133.4, 128.4, 127.9, 127.3, 125.0, 66.1, 60.0, 53.9, 52.5, 41.6, 30.5, 19.0, 13.7; HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>23</sub>H<sub>23</sub>O<sub>4</sub>, m/z: 363.1596, observed: 363.1596.



	Retention Time	Area	% Area
1	12.536	673893	2.21
2	19.831	29819112	97.79



isopropyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7bhexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate Yellow oil; 50% yield, 96:4 e.r., 97:3 d.r.; [a]<sub>D</sub><sup>25</sup> = -503.8 (c 0.44, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda$  = 254 nm, t<sub>1</sub> = 10.88 min, t<sub>2</sub> = 12.37 min, t<sub>3</sub> = 16.82 min, t<sub>4</sub> = 18.16 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.32 – 7.30 (m, 4H), 7.24 – 7.21 (m, 1H), 6.90 (s, 2H), 6.55 (s, 1H), 6.49 (d, J = 5.6 Hz, 1H), 6.31 (s, 1H), 5.10 – 4.93 (m, 1H), 3.89 (s, 1H), 3.80 – 3.75 (m, 2H), 1.23 (t, J = 6.8 Hz, 6H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.6, 193.3, 166.1, 147.1, 141.8, 140.6, 139.6, 136.5, 133.3, 128.4, 127.9, 127.3, 124.9, 70.2, 60.1, 53.8, 52.5, 41.5, 21.8;

HRMS (ESI) calcd for  $[M+H]^+$ ,  $C_{22}H_{21}O_4$ , m/z: 349.1440, observed: 349.1432.



	Retention Time	Area	% Area
1	10.864	10761614	48.56
2	12.703	190802	0.86
3	16.824	463394	2.09



	Retention Time	Area	% Area
1	10.884	345903	3.64
2	18.168	9150491	96.36



isobutyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-1,3a,4,7,7a,7b-he xahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate Yellow oil; 65% yield, 98:2 e.r., >20:1 d.r.;  $[a]_D^{25} = -567.3$  (c 0.56, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 10.52 min, t<sub>2</sub> = 15.41 min]; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.33 – 7.30 (m, 4H), 7.25 – 7.17 (m, 1H), 6.91 (s, 2H), 6.55 (s, 1H), 6.49 (d, *J* = 5.2 Hz, 1H), 6.32 (dd, *J* = 4.8, 2.4 Hz,

1H), 3.95 - 3.86 (m, 3H), 3.85 - 3.72 (m, 2H), 1.96 - 1.86 (m, 1H), 0.89 (d, J = 6.4 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  195.5, 193.2, 166.6, 147.1, 141.7, 140.6, 139.7, 136.5, 133.4, 128.4, 127.9, 127.3, 125.0, 72.1, 60.0, 53.8, 52.6, 41.6, 27.7, 18.9;

HRMS (ESI) calcd for  $[M+H]^+$ ,  $C_{23}H_{23}O$ , m/z:363.1596, observed: 363.1592.



	Retention Time	Area	% Area
1	10.521	240060	1.74
2	15.418	13571420	98.26



Methyl-(3aR,3bR,9aR,9bS)-1-((Z)-benzylidene)-4,9-dioxo-1,3a,4,9,9a,9 b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2-b]naphthalene-3b-carbo xylate;

Yellow oil; 55% yield, 98.5:1.5 e.r., 95:5 d.r.;  $[a]_D^{25} = -517.3$  (c 0.34, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak Lux 5u Cellulose-2, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =

19.34 min,t<sub>2</sub> = 20.37 min, t<sub>3</sub> = 24.71 min,t<sub>4</sub> = 26.71 min]; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.19 (dt, *J* = 4.0, 2.1 Hz, 1H), 8.17 – 8.10 (m, 1H), 7.89 – 7.76 (m, 2H), 7.34 – 7.25 (m, 4H), 7.22 – 7.13 (m, 1H), 6.54 (s, 1H), 6.52 – 6.48 (m, 1H), 6.37 (dd, *J* = 5.5, 2.9 Hz, 1H), 3.95 (dd, *J* = 10.2, 4.3 Hz, 2H), 3.79 (t, *J* = 6.6 Hz, 1H), 3.69 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  193.8, 192.3, 167.7, 147.4, 139.7, 136.6, 135.4,135.3, 134.6, 134.6, 133.7, 128.4,128.3, 128.0, 127.9, 127.5, 127.1, 124.8, 60.7, 54.1, 53.3, 53.0, 41.7. HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>24</sub>H<sub>19</sub>O<sub>4</sub>, m/z:371.1283, observed: 371.1281;





26.710

72464322

4

 $methyl-(3aR, 3bR, 7aR, 7bS)-1-((Z)-benzylidene)-4, 7-dioxo-6-phenyl-1, 3\\a, 4, 7, 7a, 7b-hexahydro-3bH-cyclopenta[3, 4]cyclobuta[1, 2]benzene-3b-c\\arboxylate$ 

Yellow oil; 50% yield, 95:5 e.r.,>20:1 d.r.;  $[a]_D^{25} = -410.7$  (c 0.43, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 20.46$  min, $t_2 = 21.71$  min];

93.54

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 – 7.45 (m, 5H), 7.35 – 7.27 (m, 4H), 7.25 – 7.21 (m, 1H), 7.03 (s, 1H), 6.56 (s, 1H), 6.52 (d, *J* = 5.6 Hz, 1H), 6.41 – 6.32 (m, 1H), 3.98 (t, *J* = 6.0 Hz, 1H), 3.92 – 3.89 (m, 1H), 3.86 (d, *J* = 6.0 Hz, 1H), 3.75 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.5, 192.9, 167.3, 151.3, 147.4, 139.8, 136.8, 135.6, 133.8, 132.7, 130.9, 129.1, 128.8, 128.4, 127.9, 127.2, 124.6, 60.6, 53.6, 53.0, 41.3; HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>26</sub>H<sub>21</sub>O<sub>4</sub>, m/z: 397.1440, observed: 397.1441.



	Retention Time	Area	% Area
1	20.460	371150	5.19
2	21.719	6773829	94.81



methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-6-(o-tolyl)-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3 b-carboxylate

Yellow oil; 68% yield, 98:2 e.r., >20:1 d.r.;  $[a]_D^{25} = -205.6$  (c 1.2, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 95/5, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 21.13$  min,  $t_2 =$ 

23.39 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.38 – 7.33 (m, 3H), 7.33 – 7.24 (m, 4H), 7.20 – 7.17 (m, 1H), 7.14 – 7.12 (m, 1H), 6.85 (s, 1H), 6.57 (s, 1H), 6.54 – 6.49 (m, 1H), 6.32 (dd, *J* = 5.6, 2.8 Hz, 1H), 4.02 – 3.98 (m, 1H), 3.94 – 3.89 (m, 2H), 3.77 (s, 3H), 2.20 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 194.7, 192.9, 167.3, 154.4, 147.1, 140.1, 138.6, 136.5, 135.9, 133.4, 130.5, 129.8, 128.9, 128.5, 128.3, 128.0, 127.2, 125.9, 125.1, 60.9, 53.7, 53.1, 52.6, 41.6, 20.4;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>27</sub>H<sub>23</sub>O<sub>4</sub>, m/z: 411.1596, observed: 411.1593.



	Retention Time	Area	% Area
1	21.128	12160583	49.35
2	22.900	12478810	50.65



	Retention Time	Area	% Area
1	21.137	10328933	98.29
2	23.397	179496	1.71



methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-6-(m-tolyl)-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benze ne-3b-carboxylate

Yellow oil; 61% yield, 90:10 e.r., >20:1 d.r.;  $[a]_D^{25} = -149.3$  (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 95/5, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 33.22 min, t<sub>2</sub>

= 34.98 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.40 – 7.26 (m, 8H), 7.24 – 7.22 (m, 2H), 7.01 (d, *J* = 1.2 Hz, 1H), 6.56 (s, 1H), 6.52 (d, *J* = 5.2 Hz, 1H), 6.41 – 6.32 (m, 1H), 4.01 – 3.95 (m, 1H), 3.92 – 3.89 (m, 1H), 3.85 (d, *J* = 6.0 Hz, 1H), 3.75 (d, *J* = 2.0 Hz, 3H), 2.43 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.5, 192.8, 167.4, 151.6, 147.5, 139.8, 138.4, 136.8, 135.5, 133.8, 132.7, 131.7, 129.7, 128.7, 128.5, 128.2, 127.9, 127.2, 126.2, 124.6, 60.7, 53.6, 52.9, 41.2, 21.5;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>27</sub>H<sub>23</sub>O<sub>4</sub>, m/z: 411.1596, observed: 411.1600.



	Retention Time	Area	% Area
1	33.228	426787	9.73
2	34.983	3959123	90.27



methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-(4-(tert-butyl)ph enyl)-4,7-dioxo-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyc lobuta[1,2]benzene-3b-carboxylate

Yellow oil; 60% yield, 98:2 e.r., 92:8 d.r.,  $[a]_D^{25} = -141.1$  (c 1.2, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 95/5, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 26.31 min,

 $t_2 = 30.81 \text{ min}, t_3 = 32.38 \text{ min}, t_4 = 34.38 \text{ min}];$ 

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 – 7.47 (m, 4H), 7.35 – 7.29 (m, 4H), 7.26 – 7.21 (m, 1H), 7.03 (s, 1H), 6.56 (s, 1H), 6.52 (d, J = 5.2 Hz, 1H), 6.37 (dd, J = 5.2, 2.8 Hz, 1H), 3.97 (t, J = 6.4 Hz, 1H), 3.89 (d, J = 3.6 Hz, 1H), 3.85 (d, J = 6.4 Hz, 1H), 3.74 (s, 3H), 1.37 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.8, 192.9, 167.4, 154.7, 151.2, 147.4, 139.8, 136.7, 134.7, 133.8, 129.7, 128.9, 128.5, 128.2, 127.9, 127.2, 125.9, 124.5, 60.7, 53.6, 52.9, 41.3, 34.9, 31.2;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>30</sub>H<sub>29</sub>O<sub>4</sub>, m/z: 453.2066, observed: 453.2061.



	Retention Time	Area	% Area
1	26.314	542697	7.95
2	30.810	78873	1.15
3	32.383	9900	0.14
4	34.381	6198131	90.75



Methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-(4-fluorophenyl)-4, 7-dioxo-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2] benzene-3b-carboxylate

Yellow oil; 50% yield, 98.5:1.5 e.r., >20:1 d.r.;  $[a]_D^{25} = -355.9$  (c 0.72, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE,

n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 17.28$  min, $t_2 = 20.25$  min]; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 – 7.51 (m, 2H), 7.33 – 7.31 (m, 1H), 7.30 – 7.29 (m, 2H), 7.28 (d, J = 1.8 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.19 – 7.13 (m, 2H), 7.00 (s, 1H), 6.56 (s, 1H), 6.52 (dd, J = 5.2, 0.8 Hz, 1H), 6.36 (dd, J = 5.6, 2.8 Hz, 1H), 3.95 (t, J = 6.4 Hz, 1H), 3.91 – 3.87 (m, 1H), 3.85 (d, J = 6.4 Hz, 1H), 3.75 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.3, 192.7, 167.3, 165.6, 163.1, 150.0, 147.4, 139.8, 138.1, 136.8, 135.4, 133.7, 131.4, 131.3, 128.7, 128.4, 127.9, 127.2, 124.6, 116.1, 115.9, 60.7, 53.6, 53.5, 53.0, 41.4;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>26</sub>H<sub>20</sub>FO<sub>4</sub>, m/z: 415.1346, observed: 415.1345.



	Retention Time	Area	% Area
1	17.076	14369770	49.60
2	19.656	14603878	50.40
	1		

₹ 0.20 0.00 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 18.00 20.00 22.00 18.00 20.00 22.00

	Retention Time	Area	% Area
1	17.289	9855230	98.59
2	20.255	141087	1.41



Methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-(4-ethoxyphenyl)-4 ,7-dioxo-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate

Yellow oil; 60% yield, 98.5:1.5 e.r., >20:1 d.r.;  $[a]_D^{25} = -331.3$  (c 0.62, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 35.70 min, t<sub>2</sub>

= 50.15 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 – 7.53 (m, 2H), 7.34 – 7.32 (m, 1H), 7.31 – 7.29 (m, 2H), 7.29 – 7,27 (m, 1H), 7.24 – 7.19 (m, 1H), 6.99 (s, 1H), 6.98 – 6.96 (m, 1H), 6.96 – 6.94 (m, 1H), 6.54 (s, 1H), 6.52 – 6.48 (m, 1H), 6.37 (dd, J = 5.2, 2.8 Hz, 1H), 4.11 (q, J = 7.2 Hz, 2H), 3.97 (t, J = 6.4 Hz, 1H), 3.87 – 3.85 (m, 1H), 3.81 (d, J = 6.4 Hz, 1H), 3.74 (s, 3H), 1.45 (t, J = 9.8, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 196.1, 192.7, 167.5, 161.5, 150.6, 147.6, 139.7, 136.8, 134.0, 133.3, 130.9, 128.5, 128.2, 127.9, 127.1, 124.5, 124.4, 114.8, 63.8, 60.6, 53.7, 53.6, 52.9, 41.2, 14.7;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>28</sub>H<sub>25</sub>O<sub>5</sub>, m/z: 441.1702, observed: 441.1701.



	Retention Time	Area	% Area
1	35.705	25739380	98.53
2	50.156	384198	1.47



methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-methyl-4,7-dioxo-1, 3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3 b-carboxylate

Yellow oil; 67% yield, 98:2 e.r., 97:3 d.r.;  $[a]_D^{25} = -453.8$  (c 0.60, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 17.35$  min,  $t_2 = 18.24$  min,  $t_3 = 20.10$  min,  $t_4 = 22.29$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 – 7.27 (m, 4H), 7.24 – 7.18 (M, 1H), 6.79 (s, 1H), 6.54 (s, 1H), 6.49 (d, J = 5.2 Hz, 1H), 6.33 – 6.28 (m, 1H), 3.85 (s, 1H), 3.75 (s, 2H), 3.73 (s, 3H), 2.15 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 196.0, 192.6, 167.4, 152.2, 147.3, 139.7, 137.8, 136.6, 133.5, 128.3, 127.9, 127.2, 124.8, 60.5, 53.6, 52.9, 52.3, 41.8, 16.9;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>21</sub>H<sub>19</sub>O<sub>4</sub>, m/z: 335.1283, observed: 335.1287.



1	17.355	508011	2.32
2	22.299	21361145	97.68



Methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-ethyl-4,7-dioxo-1,3a, 4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-car boxylate

Yellow oil; 66% yield, 98:2 e.r., 95:5 d.r.;  $[a]_D^{25} = -572.1$  (c 0.42, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 15.88 min, t<sub>2</sub> =

16.53 min,  $t_3 = 17.71 \text{ min}, t_4 = 19.63 \text{ min}$ ];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ 7.34 – 7.26 (m, 4H), 7.23 – 7.18 (m, 1H), 6.73 (d, J = 1.2 Hz, 1H), 6.54 (s, 1H), 6.48 (d, J = 5.2 Hz, 1H), 6.32 (dd, J = 5.6, 2.8 Hz, 1H), 3.87 – 3.80 (m, 1H), 3.79 – 3.74 (m, 2H), 3.73 (s, 3H), 2.67 – 2.43 (m, 2H), 1.19 (t, *J* = 7.6 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.7, 192.9, 167.4, 157.1, 147.3, 139.6, 136.6, 136.0, 133.6, 128.4, 127.9, 127.2, 124.8, 60.3, 53.6, 52.9, 52.6, 41.6, 23.3, 11.6;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>22</sub>H<sub>21</sub>O<sub>4</sub>, m/z: 349.1440, observed: 349.1441.



	Retention Time	Area	% Area
1	15.888	520910	1.55
2	19.630	33103195	98.45



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-benzylidene)-6-isopropyl-4,7-dioxo-1, 3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-c arboxylate

Yellow oil; 82% yield, 99:1 e.r., 93:7 d.r.;  $[a]_{D}^{25} = -387.5$  (c 1.2, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 30.01$  min,  $t_2 = 32.67$  min,  $t_3 = 34.63$ 

min,  $t_4 = 36.11$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 – 7.25 (m, 4H), 7.23 – 7.17 (m, 1H), 6.70 (d, J = 1.2 Hz, 1H), 6.54 (s, 1H), 6.48 (d, J = 5.6 Hz, 1H), 6.32 (dd, J = 5.6, 2.8 Hz, 1H), 3.84 – 3.80 (m, 1H), 3.79 – 3.74 (m, 2H), 3.73 (s, 3H), 3.24 – 3.09 (m, 1H), 1.18 (dd, *J* = 6.8, 5.2 Hz, 6H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.4, 193.2, 167.4, 161.1, 147.3, 139.7, 136.6, 134.5, 133.6, 128.4, 127.8, 127.2, 124.7, 60.1, 53.6, 52.9, 52.8, 41.4, 27.6, 21.5, 20.4; HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>23</sub>H<sub>23</sub>O<sub>4</sub>, m/z: 363.1596, observed: 363.1602.



	Retention Time	Area	% Area
1	30.111	6824210	41.43
2	33.390	1037179	6.30
3	35.405	1451221	8.81
4	36.961	7160211	43.47



	Retention Time	Area	% Area
1	30.013	183245	0.47
2	32.670	2586778	6.65
3	34.633	8562	0.02
4	36.114	36114930	92.86

	Retention Time	Area	% Area		
1	30.013	183245	0.50		
2	36.114	36114930	99.50		



Ph

3qa

Methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-isobutyl-4,7-dioxo -1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benze ne-3b-carboxylate

Yellow oil; 83% yield, 99:1 e.r., 98:2 d.r.;  $[a]_D^{25} = -417.1$  (c 1.26, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 24.30 min, t<sub>2</sub> = 28.58 min, t<sub>3</sub> = 31.55 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 – 7.26 (m, 4H), 7.24 – 7.19 (m, 1H), 6.72 (s, 1H), 6.54 (s, 1H), 6.49 (dd, J = 5.6, 0.8 Hz, 1H), 6.33 (dd, J = 5.6, 2.8 Hz, 1H), 3.89 – 3.84 (m, 1H), 3.78 – 3.74 (m, 2H), 3.73 (s, 3H), 2.60 – 2.47 (m, 1H), 2.34 – 2.18 (m, 1H), 2.02 – 1.85 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.7, 192.8, 167.4, 154.9, 147.3, 139.6, 137.7, 136.6, 133.6, 128.3, 127.8, 127.2, 124.8, 60.4, 53.6, 52.9, 52.6, 41.7, 39.3, 27.6, 22.8, 22.4;

HRMS (ESI) calcd for  $[M+H]^+$ ,  $C_{24}H_{25}O_4$ , m/z: 377.1753, observed: 377.1753.

		Na												/	πJ	m /	_		
0.0	» <del> </del>											- 7-			$\rightarrow$		<u> </u>		
	0.00 2	00 4.00	6.00	8.00	10.00	12.00	14.00	16.00	18.00	20.00	22.00	24.00	26.00	28.00	30.00	32.00	34.00	36.00	38.00
	0.00	4.00	0.00	0.00	10.00	12.00	14.00	10.00	10.00	20.00	22.00	24.00	20.00	20.00	00.00	02.00	04.00	00.00	00.00

	Retention Time	Area	% Area		
1	24.958	6235113	46.52		

2	29.256	904569	6.75
3	30.933	6262768	46.73



	Retention Time	Area	% Area
1	24.307	23617796	97.39
2	28.583	423677	1.75
3	31.551	208712	0.86

	Retention Time	Area	% Area		
1	24.307	23617796	99.12		
2	31.551	208712	0.88		

Ο

∬ Ĥ O

<sup>t</sup>Bu

1

CO<sub>2</sub>CH<sub>3</sub>

Pł

3ra

methyl-(3aR,3bR,7aR,7bS)-1-((Z)-benzylidene)-6-(tert-butyl)-4,7-diox o-1,3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzen e-3b-carboxylate

Yellow oil; 78% yield, 98:2 e.r., 95:5 d.r.;  $[a]_D^{25} = -437.1$  (c 0.87, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda$  = 254 nm, t<sub>1</sub> = 8.18 min, t<sub>2</sub> = 8.59 min,  $t_3 = 9.77$  min,  $t_4 = 10.46$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 – 7.24 (m, 4H), 7.22 – 7.17 (m, 1H), 6.77 (s, 1H), 6.51 (s, 1H), 6.48 (d, J = 5.2 Hz, 1H), 6.34 – 6.28 (m, 1H), 3.82 – 3.77 (m, 2H), 3.73 (s, 3H), 3.66 (d, J = 5.2 Hz, 1H), 1.35 (s, 9H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 196.1, 193.4, 167.4, 162.8, 147.3, 140.0, 136.6, 135.4, 133.6, 128.4, 127.9, 127.1, 124.5, 60.3, 53.5, 52.9, 40.9, 36.0, 29.0;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>24</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 377.1753, observed: 377.1753.



25

2	8.593	1029104	5.47
3	9.773	17443831	92.78
4	10.469	323218	1.72

	Retention Time	Area	% Area
1	9.773	17443831	98.18
2	10.469	323218	1.82



methyl-(3aR, 3bR, 7aR, 7bS)-1-((Z)-benzylidene)-6-cyclopentyl-4,7-di oxo-1,3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]ben zene-3b-carboxylate

Yellow oil; 65% yield, 99:1 e.r.,98:2 d.r.;  $[a]_D^{25} = -416.6$  (c 0.38, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE, n-hexane/i-PrOH = 93/7, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 15.03$  min,  $t_2$ 

= 22.88 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34 – 7.26 (m, 4H), 7.24 – 7.19 (m, 1H), 6.73 (d, *J* = 1.2 Hz, 1H), 6.54 (s, 1H), 6.49 (d, *J* = 5.2 Hz, 1H), 6.33 (dd, *J* = 5.6, 2.8 Hz, 1H), 3.87 – 3.81 (m, 1H), 3.7 – 3.84 (m, 2H), 3.74 (s, 3H), 3.27 – 3.14 (m, 1H), 2.21 – 2.08 (m, 1H), 2.03 – 1.91 (m, 1H), 1.86 – 1.67 (m, 4H), 1.59 – 1.48 (m, 1H), 1.49 – 1.36 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.9, 193.2, 167.4, 159.4, 147.3, 139.7, 136.7, 134.2, 133.6, 128.4, 127.8, 127.2, 124.7, 60.1, 53.7, 53.5, 52.9, 52.7, 41.4, 39.6, 32.4, 31.1, 25.3, 25.3; HRMS (ESI) calcd for  $[M+H]^+$ , C<sub>25</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 389.1753, observed: 389.1751.

AU	0.40 0.20 0.00 2.00 4.00	8.00 8.00 10.0	0 12.00 14.00	16.00	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	22.00	964 HZ - 4.00
	Retention Time	Area	% Area				
1	14.031	1061949	4.38				
2	15.183	11535932	47.54				
3	22.550	10652084	43.90				
4	24.435	1016938	4.19				
	1			Å			

₽ 0.20							- 14.057	15.03					-22.888	-24.310
0.00										A				
	20	n 4ù	n n	າ ຂກ່	n 10`00	12'00	14 0	0	16'00	18,00	20,00	22,00		24,00
	2.0	4.0	0.0	0.00	0 10.00	12.00	14.0	0	10.00	10.00	20.00	22.00		24.00
						160	dee							

	Retention Time	Area	% Area
1	14.057	41239	0.47
2	15.039	8554049	97.44
3	22.888	81685	0.93
4	24.310	101725	1.16

Retention Time		Area	% Area
1	15.039	8554049	99.05
2	22.888	81685	0.95



methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-6-cyclohexyl-4,7-dio xo-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benz ene-3b-carboxylate

Yellow oil; 72% yield, 98.5:1.5 e.r., >20:1 d.r.;  $[a]_D^{25} = -374.9$  (c 0.72, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 11.89 min, t<sub>2</sub>

= 19.97 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.29 – 7.25 (m, 4H), 7.23 – 7.16 (m, 1H), 6.65 (d, *J* = 2.0 Hz, 1H), 6.53 (s, 1H), 6.48 (d, *J* = 5.6 Hz, 1H), 6.32 (dd, *J* = 5.6, 2.8 Hz, 1H), 3.83 – 3.81 (m, 1H), 3.76 – 3.74 (m, 1H), 3.72 (s, 3H), 2.86 – 2.80 (m, 1H), 1.96 – 1.71 (m, 6H), 1.49 – 1.39 (m, 2H), 1.31 – 1.19 (m, 2H), 1.15 – 1.05 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.5, 193.2, 167.4, 160.2, 147.3, 139.7, 136.6, 134.6, 133.7, 128.4, 127.9, 127.2, 124.7, 60.1, 53.6, 53.5, 52.9, 52.7, 41.4, 37.1, 32.3, 30.8, 26.4, 26.0, 25.9;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>26</sub>H<sub>27</sub>O<sub>4</sub>, m/z: 403.1909, observed: 403.1892.



	Retention Time	Area	% Area
1	11.888	15770063	50.55
2	19.176	15424035	49.45



Methyl-(3a*R*,3b*R*,7a*R*,7b*S*)-1-((*Z*)-benzylidene)-4,7-dioxo-6-pheneth yl-1,3a,4,7,7a,7b-hexahydro-3b*H*-cyclopenta[3,4]cyclobuta[1,2]benze ne-3b-carboxylate

Yellow oil; 60% yield, 98:2 e.r., 95:5 d.r.;  $[a]_D^{25} = -407.8$  (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 17.20 min, t<sub>2</sub>

 $= 21.36 \text{ min}, t_3 = 23.12 \text{ min}, t_4 = 24.05 \text{ min}];$ 

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31 (dd, *J* = 13.2, 4.4 Hz, 4H), 7.26 (d, *J* = 2.8 Hz, 2H), 7.23 – 7.14 (m, 4H), 6.61 (s, 1H), 6.55 (s, 1H), 6.49 (d, *J* = 5.6 Hz, 1H), 6.31 (dd, *J* = 5.2, 2.8 Hz, 1H), 3.81 (s, 1H), 3.76 – 3.74 (m, 2H), 3.72 (s, 3H), 2.93 – 2.71 (m, 4H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.6, 192.7, 167.3, 154.4, 147.3, 140.0, 139.6, 137.4, 136.6, 133.6, 128.4, 127.9, 127.3, 126.5, 124.9, 60.3, 53.1, 52.9, 52.5, 41.6, 33.8, 32.1;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>28</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 425.1753, observed: 425.1748.



	Retention Time	Area	% Area
1	17.208	514154	2.12
2	21.368	23733165	97.88



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-fluorobenzylidene)-4,7-dioxo-1,3a,4,7, 7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate; Yellowoil; 77% yield, 98.5:1.5e.r.,>20:1 d.r.;  $[a]_D^{25} = -519.6$  (c 0.52, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =15.76 min,t<sub>2</sub> = 20.81 min];

<sup>13</sup>C NMR (101 MHz, CDCl3) δ 195.5, 193.0, 167.0, 163.2, 160.7, 146.7, 141.9, 140.7, 139.8, 133.2, 132.6, 129.6, 123.9, 115.5, 115.3, 59.9, 54.0, 53.1, 52.2, 41.4;

HRMS (ESI) calcd for  $[M+K]^+, C_{20}H_{15}O_4FK$ , m/z:377.0591,378.0625, observed: 377.0595,378.0647;





98.39

127868596

o ∐	CO2	СНз
		H
0	Ĥ ∕∼∖	320
ci		Jac

20.815

2

Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-chlorobenzylidene)-4,7-dioxo-1,3a,4 ,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carbox ylate;

Yellowoil; 75% yield, 97.5:2.5e.r.,>20:1 d.r.;  $[a]_D^{25} = -454.9$  (c 0.53, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =15.55 min,t<sub>2</sub> = 21.23 min];

<sup>1</sup>H NMR (400 MHz, CDCl3)  $\delta$  7.29 – 7.23 (m, 4H), 6.92 (s, 2H), 6.49-6.47 (m, 2H), 6.31 (dd, J = 5.6, 2.8 Hz, 1H), 3.94 – 3.91 (m, 1H), 3.78 (d, J = 6.8 Hz, 1H), 3.74 (s, 3H), 3.72 (d, J = 6.8 Hz, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl3) δ 195.4, 192.9, 167.0, 147.6, 141.9, 140.7, 139.8, 134.9, 133.7, 132.9, 129.2, 128.6, 123.8, 118.5, 114.7, 59.8, 54.0, 53.1, 52.0, 41.4;

HRMS (ESI) calcd for  $[M+K]^+$ ,  $C_{20}H_{15}O_4ClK$ , m/z:393.0296, 395.0266, observed: 393.0327, 395.0286;





Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-bromobenzylidene)-4,7-dioxo-1,3a,4 ,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carbo xylate;

Yellowoil; 63% yield, 97.5:2.5e.r.,>20:1 d.r.;  $[a]_D^{25} = -389.6$  (c 0.40, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 16.37 min,t<sub>2</sub> = 22.43 min];

<sup>1</sup>H NMR (400 MHz, CDCl3)  $\delta$  7.46 – 7.40 (m, 2H), 7.22 – 7.16 (m, 2H), 6.92 (s, 2H), 6.50 – 6.46 (m, 2H), 6.31 (dd, J = 5.6, 2.8 Hz, 1H), 3.93 – 3.90 (m, 1H), 3.78 (d, J = 6.8 Hz, 1H), 3.74 (s, 3H), 3.71 (d, J = 6.8 Hz, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl3) δ 195.4, 192.9, 167.0, 147.7, 141.9, 140.7, 139.8, 135.3, 133.8, 131.5, 129.5, 123.9, 121.1, 118.5, 114.7, 59.8, 54.0, 53.2, 52.0, 41.5;

HRMS (ESI) calcd for [M+K]<sup>+</sup>,C<sub>20</sub>H<sub>15</sub>O<sub>4</sub>BrK, m/z:436.9791, 438.9770, observed: 436.9763, 438.9752;



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-iodobenzylidene)-4,7-dioxo-1,3a,4,7,7 a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate;

Yellowoil; 61% yield, 97.5:2.5 e.r.,>20:1 d.r.;  $[a]_D^{25} = -395.6$  (c 0.54, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, **3ae** n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =17.28 min,t<sub>2</sub> = 23.21 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.66 – 7.59 (m, 2H), 7.09 – 7.04 (m, 2H), 6.92 (s, 2H), 6.48 (d, J = 6.4 Hz, 1H), 6.45 (s, 1H), 6.31 (dd, J = 5.2, 2.8 Hz, 1H), 3.92 – 3.89 (m, 1H), 3.77 (d, J = 6.4 Hz, 1H), 3.74 (s, 3H), 3.71 (d, J = 6.4 Hz, 1H);

CO<sub>2</sub>CH

∥ Ĥ O ∧

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.4, 192.9, 167.0, 147.9, 141.9, 140.7, 139.9, 137.5, 135.8, 133.9, 129.7, 124.0, 118.5, 114.7, 92.7, 59.8, 54.0, 53.2, 52.0, 41.5;

HRMS (ESI) calcd for  $[M+K]^+$ ,  $C_{20}H_{15}O_4IK$ , m/z:484.9652, 485.9686, observed: 484.9659, 485.9691;



	Retention Time	Area	% Area
1	17.219	28466267	49.41
2	23.458	29143011	50.59



	Retention Time	Area	% Area
1	17.283	1737738	2.40
2	23.217	70533402	97.60



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-methylbenzylidene)-4,7-dioxo-1,3a, 4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carb oxylate;

Yellowoil; 72% yield, 98:2 e.r.,>20:1 d.r.;  $[a]_D^{25} = -508.8$  (c 0.44, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =17.55 min,t<sub>2</sub> = 28.13 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.12 (d, *J* = 8.0 Hz, 2H), 7.05 (d, *J* = 8.0 Hz, 2H), 6.83 (s, 2H), 6.43 (s, 1H), 6.40 (d, *J* = 5.2 Hz, 1H), 6.18 (dd, *J* = 5.2, 2.8 Hz, 1H), 3.85 – 3.81 (m, 1H), 3.74 – 3.69 (m, 2H), 3.65 (s, 3H), 2.25 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.4, 193.1, 167.1, 146.0, 141.9, 140.6, 140.1, 137.2, 133.6, 132.6, 129.2, 128.2, 127.9, 125.0, 122.2, 59.9, 54.1, 53.1, 52.4, 41.6, 21.2;

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>21</sub>H<sub>19</sub>O<sub>4</sub>, m/z:335.1283, observed: 335.1283;



	Retention Time	Area	% Area
1	17.602	18879952	50.02
2	28.952	18862303	49.98



	Retention Time	Area	% Area
1	17.554	1728974	1.93
2	28.130	87986642	98.07

O CO<sub>2</sub>CH<sub>3</sub> H H O CH<sub>2</sub> 3ag Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-3-methylbenzylidene)-4,7-dioxo-1,3a,4, 7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxy late;

Yellowoil; 72% yield, 98.5:1.5e.r.,>20:1 d.r.;  $[a]_D^{25} = -375.3$  (c 0.34, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =15.50 min,t<sub>2</sub> = 21.34 min];

 $\dot{C}H_3$  <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 – 7.17 (m, 1H), 7.07 – 7.03 (m, 3H), 6.77 (d, *J* = 3.6 Hz, 2H), 6.57 (s, 1H), 6.46 (d, *J* = 5.6 Hz, 1H), 6.25 (dd, *J* = 5.6, 2.8 Hz, 1H), 3.77 (d, *J* = 4.8 Hz, 1H), 3.67 (s, 1H), 3.66 (s, 3H),3.52 (t, *J* = 6.3 Hz, 1H), 2.20 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  194.8, 193.2, 167.1, 147.6, 141.8, 140.4, 139.1, 136.0, 135.6, 133.5, 129.9, 128.2, 127.4, 125.8, 123.6, 59.8, 53.5, 53.0, 52.7, 41.7, 20.0; HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>21</sub>H<sub>19</sub>O<sub>4</sub>, m/z:335.1283, observed: 335.1283;





	Retention Time	Area	% Area
1	15.506	1900256	1.60
2	21.347	116697645	98.40



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-2-methylbenzylidene)-4,7-dioxo-1,3a, 4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carb oxylate;

Yellowoil; 70% yield, 97:3e.r.,>20:1 d.r.;  $[a]_D^{25} = -527.1$  (c 0.48, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 14.11$  min, $t_2 = 16.30$  min];

<sup>CH3</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.12 (t, J = 7.6 Hz, 1H), 7.06 (s, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.83 (s, 2H), 6.44 (s, 1H), 6.41 (d, J = 5.6 Hz, 1H), 6.23 - 6.18 (m, 1H), 3.81 (s, 1H), 3.75 - 3.71 (m, 2H), 3.66 (s, 3H), 2.26 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  195.3, 193.1, 167.1, 146.8, 141.9, 140.0, 138.1, 136.3, 133.0, 128.5, 128.3, 128.2, 125.3, 125.1, 59.9, 54.0, 53.1, 52.4, 41.7, 21.3; HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>21</sub>H<sub>19</sub>O<sub>4</sub>, m/z:335.1283, observed: 335.1282;





Methyl-(3aR,3bR,7aR,7bS,Z)-1-(furan-2-ylmethylene)-4,7-dioxo-1,3a,4,7,7 a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate ; yellowoil; 61% yield, 99.5:0.5 e.r.,94:6d.r.;  $[a]_D^{25} = -464.8$  (c 0.27, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIA, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 8.28 min,t<sub>2</sub> = 10.39 min,t<sub>3</sub> = 11.29 min,t<sub>4</sub> = 12.31 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.27 (s, 1H), 6.92 (s, 2H), 6.47 (dd, J = 5.4, 1.2 Hz, 1H), 6.42 – 6.38 (m, 1H), 6.35 (dd, J = 5.6, 3.2 Hz, 1H), 6.29 (d, J = 3.6 Hz, 1H), 6.27 (s, 1H), 4.09 (t, J = 6.0 Hz, 1H), 3.89 – 3.82 (m, 1H), 3.72 (s, 3H), 3.52 (d, J = 6.4 Hz, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 193.7, 193.3, 167.2, 152.3, 145.0, 142.0, 141.9, 138.6, 134.6, 111.7, 110.8, 109.9, 59.7, 53.7, 53.1, 52.9, 42.8;

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>18</sub>H<sub>15</sub>O<sub>5</sub>, m/z:311.0919, observed: 311.0915;



	Retention Time	Area	% Area
1	8.288	1031112	6.20
2	10.391	37305	0.22
3	11.293	15553016	93.56
4	12.317	1917	0.01

	Retention Time	Area	% Area
1	10.391	37305	0.24
2	11.293	15553016	99.76



Methyl-(3aR,3bR,7aR,7bS,Z)-4,7-dioxo-1-(thiophen-3-ylmethylene)-1,3a, 4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carbo xylate;

Yellow oil; 75% yield, 90:10 e.r., 97:3 d.r.;  $[a]_D^{25} = -422.5$  (c 0.40, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpakLux 5u cellulose-3, CO<sub>2</sub>/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 22.89 min, t<sub>2</sub> = 24.13 min, t<sub>3</sub> = 25.35 min, t<sub>4</sub> = 31.76 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55 (s, 1H), 7.38 (s, 1H), 7.27 (s, 1H), 6.93 (s, 2H), 6.45 (d, *J* = 4.8 Hz, 1H), 6.37 (s, 1H), 6.31 (s, 1H), 6.22 (s, 1H), 3.93 (s, 2H), 3.74 (s, 3H), 3.72 – 3.65 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.8, 193.1, 167.0, 145.8, 143.3, 141.8, 141.3, 140.9, 139.4, 132.8, 122.3, 118.5, 114.2, 109.9, 60.1, 54.0, 53.1, 52.2, 41.6;

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>18</sub>H<sub>15</sub>O<sub>4</sub>S, m/z:327.0691, observed: 327.0688;



	Retention Time	Area	% Area
1	22.489	1390204	44.40
2	24.285	1285469	41.05
3	25.318	297471	9.50

4	31.837	158058	5.05
---	--------	--------	------



	Retention Time	Area	% Area
1	22.897	310364	9.89
2	24.134	2721932	86.75
3	25.355	97971	3.12
4	31.768	7540	0.24

O CO<sub>2</sub>CH<sub>3</sub> T H H H S 3ak

2

23.205

Methyl-(3aR,3bR,7aR,7bS,Z)-1-(benzo[b]thiophen-2-ylmethylene)-4,7-di oxo-1,3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzen e-3b-carboxylate;

Yellowoil; 82% yield, 98:2e.r.,>20:1d.r.;  $[a]_D^{25} = -605.0$  (c 0.56, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIE, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =22.55 min,t<sub>2</sub> =23.20 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.80 – 7.71 (m, 1H), 7.67 (d, *J* = 4.8 Hz, 1H), 7.58 (d, *J* = 2.8 Hz, 1H), 7.36 – 7.23 (m, 2H), 6.82 (d, *J* = 3.2 Hz, 2H), 6.71 (s, 1H), 6.52 (s, 1H), 6.26 (s, 1H), 3.83 (s, 1H), 3.79 – 3.72 (m, 1H), 3.67 (d, *J* = 3.2 Hz, 3H), 3.60 - 3.58 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.9, 192.9, 167.0, 148.2, 141.9, 140.9, 139.7, 139.3, 138.6, 133.9, 131.7, 124.5, 124.2, 123.3, 122.8, 121.6, 116.2, 59.9, 53.8, 53.2, 52.1, 42.2; HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>22</sub>H<sub>17</sub>O<sub>4</sub>S, m/z:377.0848, observed: 377.0847;



98.07

112588666



Methyl-(3aR,3bR,7aR,7bS,Z)-1-(naphthalen-1-ylmethylene)-4,7-dioxo-1,3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3 b-carboxylate;

Yellowoil; 65% yield, 97:3 e.r.,>20:1 d.r.;  $[a]_D^{25} = -225.9$  (c 0.48, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> =16.40 min,t<sub>2</sub> =19.36 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.99 – 7.92 (m, 1H), 7.87 – 7.81 (m, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.53 – 7.42 (m, 4H), 7.15 (s, 1H), 6.86 – 6.76 (m, 2H), 6.66 (d, *J* = 5.6 Hz, 1H), 6.40 (dd, *J* = 5.6, 2.8 Hz, 1H), 3.86 – 3.81 (m, 1H), 3.80 (d, *J* = 6.8 Hz, 1H), 3.75 (s, 3H), 3.53 (t, *J* = 6.4 Hz, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 194.7, 193.1, 167.1, 149.2, 141.8, 140.4, 138.7, 134.2, 133.5, 131.4, 128.5, 127.8, 126.5, 126.0, 125.8, 125.5, 124.3, 122.5, 59.8, 53.4, 53.0, 52.6, 42.1; HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>24</sub>H<sub>19</sub>O<sub>4</sub>, m/z:371.1283, observed: 371.1283;



	Retention Time	Area	% Area
1	16.408	1798673	3.08
2	19.367	56632721	96.92



Methyl-(3aR,3bR,7aR,7bS,Z)-1-(naphthalen-2-ylmethylene)-4,7-dioxo-1,3 a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carb oxylate;

Yellowoil; 78% yield, 99:1 e.r.,>20:1 d.r.;  $[a]_D^{25} = -392.7$  (c 0.56, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 25.54$  min, $t_2 = 30.86$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86 (d, *J* = 8.8 Hz, 2H), 7.75 (t, *J* = 8.0 Hz, 2H), 7.47 – 7.30 (m, 2H), 7.36 (dd, *J* = 8.4, 1.2 Hz, 1H), 6.97 – 6.86 (m,

2H), 6.69 (s, 1H), 6.53 (d, *J* = 5.2 Hz, 1H), 6.31 (dd, *J* = 5.2, 2.8 Hz, 1H), 3.91 – 3.88 (m, 1H), 3.86 (s, 1H), 3.82 (t, *J* = 6.4 Hz, 1H), 3.74 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.6, 193.0, 167.1, 147.4, 141.9, 140.7, 140.0, 133.9, 133.5, 133.4, 132.6, 128.4, 127.8, 127.5, 126.6, 126.2, 125.9, 125.3, 59.9, 54.1, 53.1, 52.3, 41.8; HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>24</sub>H<sub>19</sub>O<sub>4</sub>, m/z:371.1283, observed: 371.1288;


_	Retention Time	Area	% Area
1	25.540	1461490	1.12
2	30.869	129336868	98.88

CO<sub>2</sub>CH<sub>3</sub>

ent-3an

н

AcO

4

33.456

Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-4-acetoxybenzylidene)-4,7-dioxo -1,3a,4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benze ne-3b-carboxylate;

Yellowoil; 75% yield, 98.5:1.5 e.r.,96:4d.r.;  $[a]_D^{25} = 456.1$  (c 0.43, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakOD-H, n-hexane/i-PrOH = 70/30, 1.0 mL/min,  $\lambda = 254$  nm,t<sub>1</sub>=19.18 min,t<sub>2</sub>=21.55 min,t<sub>3</sub> =33.22 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.37 – 7.29 (m, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.91 (s, 2H), 6.53 (s, 1H), 6.49 (d, J = 5.2 Hz, 1H), 6.29 (dd, J = 5.6, 2.8 Hz, 1H), 3.94 – 3.89 (m, 1H), 3.78 (t, J = 6.8 Hz, 2H), 3.73 (s, 3H), 2.29 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.4, 193.0, 169.5, 167.0, 149.7, 147.1, 141.9, 140.6, 139.8, 134.2, 133.4, 129.0, 124.2, 121.5, 59.8, 54.0, 53.1, 52.2, 41.5, 21.2;

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>22</sub>H<sub>19</sub>O<sub>6</sub>, m/z:379.1182, observed: 379.1179;

36139941





46.95

	Retention Time	Area	% Area
1	19.181	1086447	1.32
2	33.222	81281885	98.68

	Retention Time	Area	% Area
1	19.181	1086447	1.26
2	21.556	3677586	4.27
3	33.222	81281885	94.46



Methyl-(3aR,3bR,7aR,7bS,Z)-4,7-dioxo-1-((E)-3-phenylallylidene)-1,3a, 4,7,7a,7b-hexahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carb oxylate;

Yellow oil; 81% yield, 97:3 e.r.,>20:1 d.r.;  $[a]_D^{25} = -219.5$  (c 0.55, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm, t<sub>1</sub> = 23.58 min,t<sub>2</sub> = 37.14 min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.51 (d, *J* = 8.0 Hz, 2H), 7.34 (t, *J* = 8.0 Hz, 2H), 7.24 – 7.20 (m, 1H), 7.08–7.02 (m, 1H), 6.98–6.88 (m, 2H), 6.59 (d, *J* = 15.0 Hz, 1H), 6.47 (d, *J* = 4.8 Hz, 1H), 6.30 (d, *J* = 11.2 Hz, 1H), 6.25 (s, 1H), 3.93 (s, 2H), 3.74 (s, 3H), 3.70–3.67 (m, 1H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 196.0, 193.0, 167.1, 149.1, 141.9, 141.2, 138.7, 137.6, 134.6, 133.4, 128.7, 127.5, 126.6, 126.3, 124.1, 123.1, 118.5, 114.7, 61.0, 53.5, 53.2, 51.9, 41.6; HRMS (ESI) calcd for  $[M+H]^+$ , C<sub>22</sub>H<sub>19</sub>O<sub>4</sub>, m/z:347.1283, observed: 347.1286;



6. Other o-substituted quinones and substituted fulvenes which are not suitable for this [2+2] cycloaddition reaction

O-substituted quinones: no reaction under the optimal conditions



Substituted fulvenes: no reaction under the optimal conditions



#### 7. General procedure for the isomerization of the product 3aa



In a test tube with a magnetic stirring bar,  $In(OTf)_3$  (0.015 mmol)in CH<sub>3</sub>CN (1.0 mL) wasstirred at 30 °C for 30 min. **3** (0.1 mmol)in CH<sub>3</sub>CN (0.2 mL)was added in one-portion at -20 °C. The mixture was stirred at -20 °C for 15-30 min anddetected by TLC. After completion, flash column chromatography was carried out to provide the desired product **4**. The product was directed for HPLC and NMR analysis.

Methyl-(3aR,8bR)-1-((Z)-benzylidene)-7-hydroxy-3a,8b-dihydro-1H-cyclopenta[b]benzofuran-8-carboxylate;



Whiteoil; 95% yield, 99.5:0.5 e.r., 99:1d.r.;  $[a]_D^{25} = -64.7$  (c 0.38, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis[Daicel chiralpakIA, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 6.50$  min,  $t_2 = 8.32$  min,  $t_3 = 10.01$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.22 (s, 1H), 7.25 – 7.18 (m, 3H), 6.95 (d, *J* = 1.6 Hz, 1H), 6.92 (d, *J* = 8.8 Hz, 2H), 6.81 (d, *J* = 8.8 Hz, 1H), 6.68 (s, 1H), 6.58 (d, *J* = 5.6 Hz, 1H), 6.20 (dd, *J* = 5.6, 2.4 Hz, 1H), 5.71 (dd, *J* = 6.4, 2.4 Hz, 1H), 4.99 (dd, *J* = 6.4, 2.0 Hz, 1H), 3.17 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.9, 155.5, 153.4, 145.5, 143.5, 136.8, 130.8, 128.6, 128.2, 127.9, 127.0, 126.4, 117.7, 117.3, 111.8, 91.8, 51.7, 50.4;

HRMS (ESI) calcd for [M+Na]<sup>+</sup>,C<sub>20</sub>H<sub>16</sub>O<sub>4</sub>Na, m/z:343.0946, observed: 343.0947;



	Retention Time	Area	% Area
1	6.578	4224569	7.69
2	6.818	4269990	7.77

3	8.855	22618738	41.18
4	10.820	23807662	43.35



	Retention Time	Area	% Area
1	6.501	373648	1.50
2	8.320	24475547	98.08
3	10.013	104648	0.42

	Retention Time	Area	% Area
1	8.320	24475547	99.57
2	10.013	104648	0.43

Ph

0<u>-</u> H

Ĥ

4pa

H<sub>3</sub>CO<sub>2</sub>C

HO

Methyl-(3a*R*,8b*R*)-1-((*Z*)-benzylidene)-7-hydroxy-5-isopropyl-3a,8bdihydro-1*H*-cyclopenta[b]benzofuran-8-carboxylate

Colourless oil; 82% yield, 99:1e.r., 90:10 d.r.;  $[a]_D^{25} = -57.9$  (c 0.56, CH<sub>2</sub>Cl<sub>2</sub>);Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 6.22$  min,  $t_2 = 8.07$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.29 (s, 1H), 7.25 – 7.16 (m, 3H), 6.98 (t, *J* = 7.2 Hz, 2H), 6.72 (s, 1H), 6.65 (s, 1H), 6.55 (d, *J* = 5.6 Hz, 1H), 6.27 – 6.10 (m, 1H), 5.70 (dd, *J* = 6.4, 1.2 Hz, 1H), 5.00 (d, *J* = 6.4 Hz, 1H), 3.11 (s, 3H), 3.05 – 3.00 (m, 1H), 1.23 (dd, *J* = 14.0, 6.8 Hz, 6H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.9, 151.2, 145.8, 143.2, 139.7, 137.0, 131.1, 128.6, 128.1, 128.1, 127.0, 126.9, 126.1, 114.4, 109.2, 91.2, 51.5, 50.4, 28.4, 22.2, 21.6; HRMS (ESI) calcd for  $[M+H]^+$ , C<sub>23</sub>H<sub>23</sub>O<sub>4</sub>, m/z: 353.1596, observed: 353.1599.



1	6.220	590435	10.52
2	8.073	5021541	89.48



Methyl-(3a*R*,8b*R*)-1-((*Z*)-benzylidene)-7-hydroxy-5-isobutyl-3a,8b-di hydro-1*H*-cyclopenta[b]benzofuran-8-carboxylate

Colourless oil; 81% yield,97.5:2.5 e.r., 90:10 d.r.;  $[a]_D^{25} = -70.4$  (c 0.50, CH<sub>2</sub>Cl<sub>2</sub>);Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 6.37$  min,  $t_2 = 8.11$  min,  $t_3 = 10.01$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.24 (d, *J* = 1.2 Hz, 1H), 7.23 – 7.16 (m, 3H), 6.97 (d, *J* = 7.2 Hz, 2H), 6.64 (d, *J* = 8.4 Hz, 2H), 6.55 (d, *J* = 5.6 Hz, 1H), 6.24 – 6.11 (m, 1H), 5.67 (d, *J* = 6.4 Hz, 1H), 5.01 (d, *J* = 6.4 Hz, 1H), 3.12 (d, *J* = 1.2 Hz, 3H), 2.49 – 2.36 (m, 2H), 1.99 – 1.92 (m, 1H), 0.99 – 0.85 (m, 6H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.4, 152.2, 145.8, 143.1, 137.0, 132.8, 131.1, 128.7, 128.1, 126.9, 126.0, 118.3, 109.4, 91.1, 51.5, 50.6, 39.5, 28.4, 22.5;

HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>24</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 377.1753, observed: 377.1759.



	Retention Time	Area	% Area
1	6.374	560740	9.52
2	8.112	134057	2.28
3	10.016	5194777	88.20

	Retention Time	Area	% Area
1	8.112	134057	2.52
2	10.016	5194777	97.48



Methyl-(3a*R*,8b*R*)-1-((*Z*)-benzylidene)-5-cyclopentyl-7-hydroxy-3a,8 b-dihydro-1*H*-cyclopenta[b]benzofuran-8-carboxylate

Colourless oil; 80% yield,97.5:2.5e.r., 93:7d.r.;  $[a]_D^{25} = -106.6$  (c 0.36, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 7.20$  min,  $t_2 = 8.75$  min,  $t_3 = 10.41$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.28 (s, 1H), 7.24 – 7.19 (m, 3H), 7.03 – 6.90 (m, 2H), 6.72 (s, 1H), 6.66 (s, 1H), 6.56 (d, J = 5.6 Hz, 1H), 6.19 (dd, J = 5.6, 2.4 Hz, 1H), 5.69 (dd, J = 6.4, 2.4 Hz, 1H), 4.99 (dd, J = 6.4, 1.6 Hz, 1H), 4.04 (s, 0H), 3.17 – 3.03 (m, 4H), 2.10 – 1.94 (m, 2H), 1.86 – 1.74 (m, 2H), 1.73 – 1.61 (m, 3H), 1.50 – 1.55 (m, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.8, 151.8, 145.8, 143.2, 137.6, 137.0, 131.1, 128.6, 128.1, 126.9, 129.9, 126.1, 115.0, 109.1, 91.2, 51.4, 50.5, 40.1, 32.9, 32.3, 25.4; HRMS (ESI) calcd for  $[M+H]^+$ , C<sub>25</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 389.1753, observed: 389.1752.



	Retention Time	Area	% Area
1	8.752	128548	2.26
2	10.411	5547151	97.74

Methyl-(3a*R*,8b*R*)-1-((*Z*)-benzylidene)-7-hydroxy-5-phenyl-3a,8b-d ihydro-1*H*-cyclopenta[b]benzofuran-8-carboxylate



Colourless oil; 90% yield,98.5:1.5 e.r., 90:10 d.r.;  $[a]_D^{25} = -166.8$  (c 0.60, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 10.58$  min,  $t_2 = 11.83$  min,  $t_3 = 14.91$  min,  $t_4 = 17.84$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.29 (s, 1H), 7.72 – 7.65 (m, 2H), 7.47 – 7.40 (m, 2H), 7.39 – 7.29 (m, 2H), 7.25 – 7.20 (m, 2H), 7.00

(s, 1H), 6.96 (dd, J = 7.2, 1.6 Hz, 2H), 6.71 (s, 1H), 6.58 (d, J = 5.6 Hz, 1H), 6.28 – 6.16 (m, 1H), 5.74 (dd, J = 6.4, 2.0 Hz, 1H), 5.03 (dd, J = 6.4, 2.0 Hz, 1H), 3.21 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  169.8, 155.5, 150.9, 145.7, 143.5, 136.8, 135.9, 131.0, 129.0, 128.7, 128.6, 128.2, 128.1, 127.0, 126.5, 116.9, 110.9, 91.8, 51.6, 50.3; HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>26</sub>H<sub>21</sub>O<sub>4</sub>, m/z: 397.1440, observed: 397.1440.



	Retention Time	Area	% Area
1	14.910	74627	1.47
2	17.841	4999181	98.53



Methyl-(3a*R*,8b*R*)-1-((*Z*)-benzylidene)-7-hydroxy-5-phenethyl-3a,8b -dihydro-1*H*-cyclopenta[b]benzofuran-8-carboxylate

Colourless oil; 85% yield, 98.5:1.5 e.r., 90:10 d.r.;  $[a]_D^{25} = -72.6$  (c 0.35, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 98/2, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 9.98$  min,  $t_2 = 10.75$  min,  $t_3 = 15.17$  min,  $t_4 = 17.57$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.25 (d, J = 1.6 Hz, 1H), 7.25 – 7.14 (m, 8H), 6.93 (d, J = 6.8 Hz, 2H), 6.67 (s, 1H), 6.62 (s, 1H), 6.56 (d, J = 5.2 Hz, 1H), 6.23 – 6.11 (m, 1H), 5.67 (d, J = 6.4 Hz, 1H), 4.97 (d, J = 6.4 Hz, 1H), 3.14 (d, J = 1.6 Hz, 3H), 2.94 – 2.80 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.1, 155.6, 151.9, 145.7, 143.3, 141.4, 136.9, 132.5, 130.9,

128.5, 128.3, 128.1, 127.2, 126.9, 126.2, 125.9, 117.6, 109.6, 915, 51.5, 50.6, 35.1, 32.3; HRMS (ESI) calcd for [M+H]<sup>+</sup>, C<sub>28</sub>H<sub>25</sub>O<sub>4</sub>, m/z: 425.1753, observed: 425.1757.



	Retention Time	Area	% Area
1	9.950	468971	8.61
2	10.698	474580	8.71
3	15.180	2220231	40.76



	Retention Time	Area	% Area
1	9.986	51431	0.61
2	10.756	892502	10.51
3	15.174	169494	2.00
4	17.575	7379159	86.89

	Retention Time	Area	% Area
1	15.174	188796	2.48
2	17.575	7431882	97.52

Methyl-(3aS,8bS)-1-((Z)-4-acetoxybenzylidene)-7-hydroxy-3a,8b-dih ydro-1H-cyclopenta[b]benzofuran-8-carboxylate;



White oil; 95% yield, 99:1 e.r., 99:1 d.r.;  $[a]_D^{25} = 118.9$  (c 0.56, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IE, n-hexane/i-PrOH = 80/20, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 14.34$  min,  $t_2 = 16.78$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.20 (s, 1H), 6.96 (s, 4H), 6.92 (d, *J* = 8.8 Hz, 1H), 6.81 (d, *J* = 8.8 Hz, 1H), 6.63 (d, *J* = 1.2 Hz, 1H), 6.57

(d, *J* = 5.6 Hz, 1H), 6.20 (dd, *J* = 5.2, 2.0 Hz, 1H), 5.71 (dd, *J* = 6.4, 2.4 Hz, 1H), 5.00 (dd, *J* = 6.4, 2.0 Hz, 1H), 3.26 (s, 3H), 2.31 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.8, 169.5, 155.4, 153.4, 149.6, 146.0, 143.3, 134.5, 131.1, 129.6, 127.7, 125.4, 121.4, 117.8, 117.3, 111.8, 91.7, 51.8, 50.3, 21.2.

HRMS (ESI) calcd for [M+Na]<sup>+</sup>,C<sub>22</sub>H<sub>18</sub>O<sub>6</sub>Na, m/z:401.1001, observed: 401.1000;



	Retention Time	Area	% Area
1	14.348	61921628	99.04
2	16.787	597984	0.96

#### 8. Gram-scale synthesis of the product 3aa and ent-3an



**Procedure a**: In a test tube with a magnetic stirring bar, N,N-dioxide L-RaPr3 (0.55 mmol), Cu(OTf)<sub>2</sub> (0.50 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were stirred at 35 °C for 1h. After removing CH<sub>2</sub>Cl<sub>2</sub> and adding CH<sub>3</sub>CN (50.0mL), quinone (1a) (5.0 mmol), 3Å MS (500 mg), and fulvene (2a) (7.5 mmol, 1.5 equiv) were added in sequence at -40 °C. The mixture was stirred at -40 °C for 36 h and detected by TLC. After completion, flash column chromatography was carried out to provide the desired product (3aa). The product was used immediately for HPLC and NMR analysis.

**Procedure b:** In a test tube with a magnetic stirring bar, *N*,*N*'-dioxide **ent-L-RaPr3**(0.55 mmol), Cu(OTf)<sub>2</sub> (0.50 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50.0 mL) were stirred at 35 °C for 1h. After removing CH<sub>2</sub>Cl<sub>2</sub> and adding CH<sub>3</sub>CN (50.0 mL), quinone (**1a**) (5.0 mmol), 3Å MS (500 mg), and fulvene (**2n**) (7.5 mmol, 1.5 equiv) were added in sequence at -40 °C. The mixture was stirred at -40 °C for 36 h and detected by TLC. After completion, flash column chromatography was carried out to provide the desired product (**ent-3an**). The product was used immediately for HPLC and NMR analysis.

### 9. Synthetic transformations of the product 3aa and ent-3an



A suspension of  $[Ir(COD)(PCy_3)(Py)]PF_6$  (16 mg) and **3aa** (65 mg) in THF (3 mL) was stirred at 0 °C under 40 atm hydrogen atmosphere. After being stirred for 16 h, the mixture was filtrated through a pad of Celite and the filtration was concentrated in

vacuo, and there sidue was purified by column chromatography on silica gel to afford the desired product **5aa**.



Methyl-(3aR,3bR,7aR,7bS)-1-((Z)-benzylidene)-4,7-dioxo-1,2,3,3a,4,7,7a,7 b-octahydro-3bH-cyclopenta[3,4]cyclobuta[1,2]benzene-3b-carboxylate; White oil; 88% yield, 99:1 e.r.,99:1d.r.;  $[a]_D^{25} = -346.6$  (c 1.08, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IA, n-hexane/i-PrOH = 93/7, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 12.07$  min,  $t_2 = 12.75$  min,  $t_3 = 15.04$  min,  $t_4 = 15.69$  min];

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.44 (d, *J* = 7.6 Hz, 2H), 7.34 (t, *J* = 7.6 Hz, 2H), 7.22 (t, *J* = 7.2 Hz, 1H), 6.54 – 6.43 (m, 2H), 6.14 (d, *J* = 2.8 Hz, 1H), 4.06 (s, 1H), 3.84 – 3.80 (m, 2H), 3.77 (s, 3H), 3.14 – 2.96 (m, 2H), 2.93 – 2.77 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 206.2, 203.0, 167.7, 147.3, 144.5, 140.5, 136.5, 133.2, 128.4, 128.2, 127.1, 124.5, 100.0, 63.9, 54.8, 54.7, 53.1, 52.9, 39.9, 38.0.

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>20</sub>H<sub>19</sub>O<sub>4</sub>, m/z: 371.1283, observed: 371.1281;



	Retention Time	Area	% Area
1	12.076	296885	0.47
2	12.759	66916	0.11
3	15.041	562611	0.88
4	15.690	62770797	98.55



**Step 1**: Recrystallization by using petroleum ether/EtOAc gave the product **ent-3an** in 88% yield with 99:1 d.r., 99:1 e.r..

**Step 2**:In a test tube with a magnetic stirring bar, **ent-3an** (3.3 mmol) in CH<sub>3</sub>CN (60 mL) was cooled to -20 °C. In(OTf)<sub>3</sub> (0.33 mmol) in CH<sub>3</sub>CN (13.0 mL) was stirred at 30 °C for 30 min. Then In(OTf)<sub>3</sub> (0. 33mmol) in CH<sub>3</sub>CN (13.0 mL) was added in one-portion at -20 °C. The mixture was stirred at -20 °C for 1.5 h and detected by TLC. After completion, flash column chromatography was carried out to provide the desired product **ent-4an**.

**Step 3**:A suspension of  $[Ir(COD)(PCy_3)(Py)]PF_6$  (250 mg) and **ent-4an** (1.19 g) in THF (30 mL) was stirred at 0 °C under 40 atm hydrogen atmosphere. After being stirred for 16 h, the mixture was filtrated through a pad of Celite and the filtration was concentrated in vacuo, and there sidue was purified by column chromatography on silica gel to afford the desired product **ent-6an**.



Methyl-(3aS,8bS)-1-((Z)-4-acetoxybenzylidene)-7-hydroxy-2,3,3a,8b -tetrahydro-1H-cyclopenta[b]benzofuran-8-carboxylate;

White oil; 99% yield, 99:1 e.r., 99:1d.r.;  $[a]_D^{25} = 128.9$  (c 0.95, CH<sub>2</sub>Cl<sub>2</sub>); Determined by HPLC analysis [Daicel chiralpak IC, n-hexane/i-PrOH = 90/10, 1.0 mL/min,  $\lambda = 254$  nm,  $t_1 = 15.93$  min,  $t_2 = 18.85$  min, $t_3 = 22.38$  min, $t_4 = 25.85$  min];

**ent-6an** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  10.23 (s, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 6.40 (s, 1H), 5.31 (t, J = 6.0 Hz, 1H), 5.20 (d, J = 7.2 Hz, 1H), 3.10 (s, 3H), 2.47 – 2.39 (m, 1H), 2.30 (s, 3H), 2.29 – 2.26 (m, 1H), 2.12 - 2.09 (m, 1H), 1.99 – 1.92 (m, 1H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.2, 169.6, 155.6, 153.8, 149.3, 144.9, 141.1, 135.7, 129.5, 127.6, 123.1, 121.7, 117.6, 116.3, 110.5, 87.4, 52.1, 49.4, 34.3, 33.5, 21.1.

HRMS (ESI) calcd for [M+H]<sup>+</sup>,C<sub>22</sub>H<sub>20</sub>O<sub>6</sub>Na, m/z: 381.1338, observed: 381.1694;



	Retention Time	Area	% Area			
1	16.189	5608032	46.01			
2	18.799	5796700	47.55			
3	22.618	430843	3.53			
4	25.902	354474	2.91			
	2.00- ₹ 1.00- 0.00 2.00 4.00	6.00 8.00 10.00	日 12.00 14.00 16.0 分钟	998.82 00 18.00 20.0	486:27 00 22.00 24.00	858 527 26.00
	Retention Time	Area	% Area			
1	15.936	118756119	99.85			
2	18.850	27509	0.02			
3	22.384	14744	0.01			
4	25.858	141946	0.12			

## ${\bf 10.X}{\bf -ray\ crystal structure\ of\ the\ product\ 3aa\ and\ ent-4an}$

## X-ray crystals structure of the product 3aa:

Empirical formula	$C_{20}H_{16}O_4$
Formula weight	320.33
Temperature/K	294.39(10)
Crystal system	monoclinic
Space group	C2
a/Å	16.8740(4)
b/Å	8.2225(2)
c/Å	11.5745(3)
$\alpha/^{\circ}$	90
β/°	92.962(2)
γ/°	90
Volume/Å <sup>3</sup>	1603.79(7)
Z	4
$\rho_{calc}g/cm^3$	1.327
$\mu/\text{mm}^{-1}$	0.754
F(000)	672.0
Crystal size/mm <sup>3</sup>	0.8 imes 0.5 imes 0.2

Radiation	$CuK\alpha \ (\lambda = 1.54184)$
20 range for data collection/°	10.5 to 134.152
Index ranges	$\textbf{-20} \leq h \leq 19,  \textbf{-9} \leq k \leq 9,  \textbf{-13} \leq \textbf{l} \leq \textbf{13}$
Reflections collected	8300
Independent reflections	2782 [ $R_{int} = 0.0293, R_{sigma} = 0.0288$ ]
Data/restraints/parameters	2782/1/218
Goodness-of-fit on F <sup>2</sup>	1.074
Final R indexes [I>= $2\sigma$ (I)]	$R_1 = 0.0508, wR_2 = 0.1295$
Final R indexes [all data]	$R_1 = 0.0517, wR_2 = 0.1316$
Largest diff. peak/hole / e Å <sup>-3</sup>	0.42/-0.24
Flack parameter	-0.08(12)



# X-ray crystal structure of product ent-4an:

Empirical formula	$C_{22}H_{18}O_{6}$
Formula weight	378.36
Temperature/K	125
Crystal system	monoclinic
Space group	P21
a/Å	7.67071(16)
b/Å	13.2339(2)
c/Å	9.6030(2)
$\alpha/\circ$	90
β/°	112.936(3)
γ/°	90
Volume/Å <sup>3</sup>	897.77(4)
Z	2
$\rho_{calc}g/cm^3$	1.400
$\mu/mm^{-1}$	0.850
F(000)	396.0
Crystal size/mm <sup>3</sup>	0.8 imes 0.5 imes 0.3

Radiation	$CuK\alpha \ (\lambda = 1.54184)$
2 $\Theta$ range for data collection/ <sup>c</sup>	° 10.002 to 134.11
Index ranges	$-7 \le h \le 9, -15 \le k \le 15, -11 \le l \le 9$
Reflections collected	8864
Independent reflections	3210 [ $R_{int} = 0.0244$ , $R_{sigma} = 0.0241$ ]
Data/restraints/parameters	3210/1/256
Goodness-of-fit on F <sup>2</sup>	1.063
Final R indexes [I>= $2\sigma$ (I)]	$R_1 = 0.0430, wR_2 = 0.1124$
Final R indexes [all data]	$R_1 = 0.0433, wR_2 = 0.1129$
Largest diff. peak/hole / e Å-3	0.32/-0.31
Flack parameter	0.03(7)



### **11.Operando IR experiments**

Static stateand Operando IR experiments:



Step 1: We initiated our studies by detecting the static state spectrogram of the substrates 1a, 2n, and the products ent-3an, ent-4an. The static state spectrogram and the characteristic IR peaks of 1a, 2n, ent-3an and ent-4an were established.



**Step 2**: We did Operando IR experimentsand detected the characteristic IR peaks (1a, 2n, ent-3ao and ent-4an). From the spectrogram we could obtain the variation trend of different compound. As illustrated in the spectrogram, when the substrate 1a was added the absorption at 1668 cm<sup>-1</sup>appeared (blue line). After the substrate 2n was added (redline), the reaction begun. As the peaks at 1668 and 1629cm<sup>-1</sup> related to the substrate 1a and 2n depleted gradually, the peaks of the product ent-3an at 1246 cm<sup>-1</sup>(greenline) and ent-4an at 1453cm<sup>-1</sup>(purpleline) increased. It indicates that product ent-3an and ent-4an generate at same time instead of the product ent-3an transform to ent-4an.



















































































































